rs149078011
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM1BP4BS2
The NM_000432.4(MYL2):c.459G>C(p.Lys153Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000044 in 1,613,004 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. K153E) has been classified as Uncertain significance.
Frequency
Consequence
NM_000432.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MYL2 | NM_000432.4 | c.459G>C | p.Lys153Asn | missense_variant | 7/7 | ENST00000228841.15 | |
MYL2 | NM_001406745.1 | c.417G>C | p.Lys139Asn | missense_variant | 6/6 | ||
MYL2 | NM_001406916.1 | c.402G>C | p.Lys134Asn | missense_variant | 7/7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MYL2 | ENST00000228841.15 | c.459G>C | p.Lys153Asn | missense_variant | 7/7 | 1 | NM_000432.4 | P1 | |
MYL2 | ENST00000548438.1 | c.417G>C | p.Lys139Asn | missense_variant | 6/6 | 3 | |||
MYL2 | ENST00000663220.1 | c.402G>C | p.Lys134Asn | missense_variant | 7/7 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 151868Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000361 AC: 9AN: 249336Hom.: 0 AF XY: 0.0000296 AC XY: 4AN XY: 134944
GnomAD4 exome AF: 0.0000452 AC: 66AN: 1461136Hom.: 0 Cov.: 31 AF XY: 0.0000468 AC XY: 34AN XY: 726868
GnomAD4 genome AF: 0.0000329 AC: 5AN: 151868Hom.: 0 Cov.: 31 AF XY: 0.0000270 AC XY: 2AN XY: 74146
ClinVar
Submissions by phenotype
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 21, 2019 | proposed classification - variant undergoing re-assessment, contact laboratory - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 15, 2021 | Variant summary: MYL2 c.459G>C (p.Lys153Asn) results in a non-conservative amino acid change located in the EF-hand domain (IPR002048) positioned in the last exon of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 249336 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.459G>C has been reported in the literature in individuals affected with Hypertrophic Cardiomyopathy (examples: Bick_2012, Walsh_2017, and Ho_2018). These reports do not provide unequivocal conclusions about association of the variant with Hypertrophic Cardiomyopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Hypertrophic cardiomyopathy 10 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 08, 2024 | This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 153 of the MYL2 protein (p.Lys153Asn). This variant is present in population databases (rs149078011, gnomAD 0.006%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 27532257, 30297972). ClinVar contains an entry for this variant (Variation ID: 43478). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Feb 15, 2023 | This missense variant replaces lysine with asparagine at codon 153 of the MYL2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 27532257, 30297972). This variant has been identified in 10/280724 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 17, 2023 | Reported in patients with HCM in published literature (Walsh et al., 2017; Ho et al., 2018); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27532257, 22958901, 30297972) - |
Hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Nov 30, 2023 | This missense variant replaces lysine with asparagine at codon 153 of the MYL2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 27532257, 30297972). This variant has been identified in 10/280724 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 29, 2020 | The c.459G>C (p.K153N) alteration is located in exon 7 (coding exon 7) of the MYL2 gene. This alteration results from a G to C substitution at nucleotide position 459, causing the lysine (K) at amino acid position 153 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at